CDH1 and breast carcinoma: Furthermore, the immunohistochemical analysis of individual tumor samples showed that I2 treatment in patients with early breast cancer and in co-adjuvant (FEC/TE + I2) treatment in patients with advanced tumors tended to increase the expression of membrane localized E-cadherin (CDH1) (Figure S2B).